MarketInOut Stock Screener Log In | Sign Up
 

Moleculin Biotech Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/16/2026 16:00
Moleculin Biotech Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6.02 mln
Float18.48 mln
Earnings Date11/13/2026

EPS

8.98
Strong

P / E

0.03
Anomalous

Piotroski F-Score

3 / 9
Below average

Relative Strength

3 / 100
Severely lagging

Debt / Equity

0.03
Debt-free

ROE

-1,972
Deeply negative

Business Description

Moleculin Biotech is a Houston-based pharmaceutical company focused on developing treatments for cancer and viral diseases. Its most advanced drug, Annamycin, is currently in clinical trials for certain forms of leukemia and lung tumors. The company is also working on two additional drug families ? one aimed at disrupting the signaling processes that allow brain, pancreatic, and other cancers to grow, and another designed to cut off the energy supply that tumors depend on to survive.

Key Fundamentals

EPS8.98
P/E0.03
ROE-1,972
ROIC-199
ROA-140
Interest Cover-370
EBITDA, mln-30.20
EV / EBITDA0.02
EV / EBIT0.02

Quote Details

Last 0.2804
Change -0.0897 (-24.24%)
Open 0.31
Volume 1,175,756
Turnover 329,682
Average Volume 1,106,057

Financial Ratios

Leverage Ratio1.82
Current Ratio0.94
Price / Book0.31
Price / Tangible Book8.34
Debt / Equity0.03

Financial Strength

Piotroski F-Score 3 / 9
Short Ratio0.17
Short % of Float1.01

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -36.56% 2 / 100   
1 Month -64.05% 1 / 100   
2 Months -87.31% 1 / 100   
6 Months -88.41% 2 / 100   
1 Year -97.8% 2 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us